Malin rethinks next move on Poseida as new options emerge

7th April, 2019

Malin is considering options other than a stock market listing to cash in on its stake in drug company Poseida – including a potential sale.

Malin owns a third of Poseida, which develops treatments for cancer using gene and cell therapy. In January the company announced it was preparing to float on the US stock market this year.

However, speaking to The Sunday Business Post, Darragh Lyons, Malin’s chief business and finance officer, said a...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Related Stories

Tom Maguire: Tax changes we make now could help business for years

More Business Tom Maguire 6 months ago

The Daily Briefing

The Daily Briefing